Sugaya K, Clamp C, Bryan D, McKinney M
Department of Pharmacology, Mayo Clinic Jacksonville, FL 32224, USA.
Brain Res Mol Brain Res. 1997 Oct 15;50(1-2):305-13. doi: 10.1016/s0169-328x(97)00199-x.
A number of pharmacological, anatomical, and immunological studies have previously addressed the subtype identity of the hippocampal muscarinic pre-synaptic autoreceptor. A preponderance of findings indicate that it is of the M2 pharmacological type. Both the m2 and m4 molecular subtypes exhibit M2 pharmacology and there are few drugs that differentiate between these receptors. Pharmacological attempts at defining the hippocampal autoreceptor have yielded conflicting results. The basal forebrain is relatively enriched in m2 muscarinic receptor mRNA and protein, and lesions that denervate the hippocampus of its basal forebrain cholinergic input have shown a decrement in m2, but not m4, receptor protein in the hippocampus. Thus, the anatomical data obtained to date tend to support the view that the m2 subtype is expressed as the hippocampal autoreceptor. We have combined in situ hybridization histochemistry (ISHH) with immunocytochemistry to choline acetyltransferase to examine whether mRNA for the m4 subtype of muscarinic receptor is expressed in central cholinergic neurons. The m4 muscarinic mRNA was found at moderate levels in all subdivisions of the cholinergic basal forebrain, including the medial septum/diagonal band complex (MS/DB). The m4 mRNA was also found in striatal cholinergic interneurons, in the cholinergic reticular core of the upper brainstem, and in brainstem cholinergic motor neurons. Muscarinic m4 receptor mRNA was also found in many non-cholinergic cells in the brain. For example, the hippocampal pyramidal neurons, dentate gyrus granule cells, and entorhinal cortical pyramidal neurons express relatively high levels of m4 mRNA, while in the brainstem the dorsal raphe and pontine reticular nuclei express relatively high levels of this mRNA. The finding of m4 mRNA in the MS/DB cholinergic neurons suggests that this receptor protein might be expressed as an autoreceptor in hippocampal cholinergic terminals.
此前,多项药理学、解剖学和免疫学研究探讨了海马毒蕈碱突触前自身受体的亚型特性。大量研究结果表明,它属于M2药理学类型。m2和m4分子亚型均表现出M2药理学特性,且很少有药物能够区分这两种受体。通过药理学方法确定海马自身受体的研究结果相互矛盾。基底前脑相对富含m2毒蕈碱受体mRNA和蛋白质,而去神经支配海马基底前脑胆碱能输入的损伤显示,海马中m2受体蛋白减少,而m4受体蛋白未减少。因此,迄今为止获得的解剖学数据倾向于支持m2亚型作为海马自身受体表达的观点。我们将原位杂交组织化学(ISHH)与胆碱乙酰转移酶免疫细胞化学相结合,以研究毒蕈碱受体m4亚型的mRNA是否在中枢胆碱能神经元中表达。在胆碱能基底前脑的所有亚区,包括内侧隔/斜角带复合体(MS/DB),均发现中等水平的m4毒蕈碱mRNA。在纹状体胆碱能中间神经元、上脑干的胆碱能网状核心以及脑干胆碱能运动神经元中也发现了m4 mRNA。在大脑的许多非胆碱能细胞中也发现了毒蕈碱m4受体mRNA。例如,海马锥体细胞、齿状回颗粒细胞和内嗅皮质锥体细胞表达相对较高水平的m4 mRNA,而在脑干中,中缝背核和脑桥网状核表达相对较高水平的这种mRNA。在MS/DB胆碱能神经元中发现m4 mRNA表明,这种受体蛋白可能作为海马胆碱能终末的自身受体表达。